Steve Abella

497 total citations
21 papers, 386 citations indexed

About

Steve Abella is a scholar working on Genetics, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Steve Abella has authored 21 papers receiving a total of 386 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 6 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Steve Abella's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Steve Abella is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Steve Abella collaborates with scholars based in United States, France and Poland. Steve Abella's co-authors include Leonard M. Klein, Jeff P. Sharman, Kathryn S. Kolibaba, Michael Boxer, Jing Hu, Michael Hawkins, Meihua Wu, Jill Kelly, Thomas L. Slovis and Edward I. Ginns and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Steve Abella

21 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steve Abella United States	9	133	114	110	79	68	21	386
Shinya Rai Japan	11	162 1.2×	150 1.3×	128 1.2×	64 0.8×	71 1.0×	47	385
Djillali Sahali France	7	41 0.3×	78 0.7×	159 1.4×	85 1.1×	19 0.3×	13	423
Kimberly F. Kerstann United States	5	69 0.5×	82 0.7×	174 1.6×	41 0.5×	137 2.0×	9	400
Sara Santos Franco United Kingdom	8	113 0.8×	19 0.2×	154 1.4×	46 0.6×	78 1.1×	10	380
Alice Huntsman Labed United States	4	70 0.5×	36 0.3×	112 1.0×	241 3.1×	27 0.4×	6	433
Jamil Dierov United States	11	115 0.9×	101 0.9×	412 3.7×	144 1.8×	161 2.4×	15	733
Hima V. Vangapandu United States	12	96 0.7×	79 0.7×	241 2.2×	49 0.6×	57 0.8×	17	460
Catia Lo Pardo Italy	14	85 0.6×	60 0.5×	266 2.4×	78 1.0×	78 1.1×	18	507
Emilie‐Fleur Gautier France	10	118 0.9×	23 0.2×	319 2.9×	42 0.5×	52 0.8×	21	588
Arshad A. Pandith India	14	87 0.7×	47 0.4×	323 2.9×	35 0.4×	114 1.7×	68	604

Countries citing papers authored by Steve Abella

Since Specialization

Citations

This map shows the geographic impact of Steve Abella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steve Abella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steve Abella more than expected).

Fields of papers citing papers by Steve Abella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steve Abella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steve Abella. The network helps show where Steve Abella may publish in the future.

Co-authorship network of co-authors of Steve Abella

This figure shows the co-authorship network connecting the top 25 collaborators of Steve Abella. A scholar is included among the top collaborators of Steve Abella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steve Abella. Steve Abella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chawla, Sant P., Vivek Subbiah, Nam Q. Bui, et al.. (2023). 1939P phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients. Annals of Oncology. 34. S1041–S1041. 1 indexed citations

Choi, Woonyoung, David J. McConkey, Graeme Currie, et al.. (2020). Abstract PR09: Gene expression profiling in wild-type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab. Clinical Cancer Research. 26(15_Supplement). PR09–PR09. 1 indexed citations

Siefker‐Radtke, Arlene O., Iwona Ługowska, Krzysztof Tupikowski, et al.. (2019). Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22. Annals of Oncology. 30. v365–v365. 13 indexed citations

Necchi, Andrea, Daniel Castellano, Begoña Mellado, et al.. (2019). PD47-08 FIERCE-21: PHASE 2 STUDY OF VOFATMAB (B-701), A SELECTIVE INHIBITOR OF FGFR3, AS SALVAGE THERAPY IN METASTATIC UROTHELIAL CARCINOMA (MUCC). The Journal of Urology. 201(Supplement 4). 3 indexed citations

Bellmunt, Joaquim, Joel Picus, Manish Kohli, et al.. (2018). FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).. Journal of Clinical Oncology. 36(15_suppl). 4534–4534. 20 indexed citations

Gopal, Ajay K., Brad S. Kahl, Christopher R. Flowers, et al.. (2015). Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. Blood. 126(23). 2744–2744. 8 indexed citations

Sharman, Jeff P., Andrei R. Shustov, Mitchell R. Smith, et al.. (2015). Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling. Blood. 126(23). 1744–1744. 3 indexed citations

Sharman, Jeff P., Michael Hawkins, Kathryn S. Kolibaba, et al.. (2015). An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 125(15). 2336–2343. 145 indexed citations

Sharman, Jeff P., Leonard M. Klein, Michael Boxer, et al.. (2015). Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Indolent Non-Hodgkin's Lymphoma (iNHL). Blood. 126(23). 1545–1545. 12 indexed citations

10.

Gopal, Ajay K., Andrew Davies, Ian W. Flinn, et al.. (2015). Idelalisib Monotherapy and Durable Responses in Patients with Relapsed or Refractory Small Lymphocytic Lymphoma (SLL). Blood. 126(23). 2743–2743. 2 indexed citations

11.

Minden, Mark D., Wendy Stock, Howland E. Crosswell, et al.. (2015). A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL). Blood. 126(23). 4866–4866. 2 indexed citations

12.

Sharman, Jeff P., Leonard M. Klein, Michael Boxer, et al.. (2015). Phase 2 Trial of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). Blood. 126(23). 4152–4152. 3 indexed citations

13.

Sharman, Jeff P., Leonard M. Klein, Michael Boxer, et al.. (2014). Phase 2 Trial of Entospletinib (GS-9973), a Selective SYK Inhibitor, in Follicular Lymphoma (FL). Blood. 124(21). 4419–4419. 3 indexed citations

14.

Juan, Gloria, Kelly Hanestad, Kathleen S. Keegan, et al.. (2013). AMG 900, a Potent and Highly Selective Aurora Kinase Inhibitor Shows Promising Preclinical Activity Against Acute Myeloid Leukemia Cell Lines In Vitro and In Vivo. Blood. 122(21). 3823–3823. 2 indexed citations

15.

Abella, Steve, Alvydas Česas, Adina Croitoru, et al.. (2013). Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC).. Journal of Clinical Oncology. 31(4_suppl). LBA445–LBA445. 4 indexed citations

16.

Gregory, Stephanie A., Steve Abella, & Timothy M. Moore. (2011). Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies. Community Oncology. 8(7). 311–325. 3 indexed citations

17.

Peres, Edward, Süreyya Savaşan, Barbara Cushing, Steve Abella, & Anwar N. Mohamed. (2003). Chromosome analyses of 16 cases of Wilms tumor: different pattern in unfavorable histology. Cancer Genetics and Cytogenetics. 148(1). 66–70. 14 indexed citations

18.

Chandrasekar, Pranatharthi, George Alangaden, Geetha Chalasani, et al.. (2001). Low Infectious Morbidity after Intensive Chemotherapy and Autologous Peripheral Blood Progenitor Cell Transplantation in the Outpatient Setting for Women with Breast Cancer. Clinical Infectious Diseases. 32(4). 546–551. 15 indexed citations

19.

Sidransky, Ellen, Robert Lee, Leon A. Metlay, et al.. (1996). Epidermal Abnormalities May Distinguish Type 2 from Type 1 and Type 3 of Gaucher Disease. Pediatric Research. 39(1). 134–141. 72 indexed citations

20.

Slovis, Thomas L., et al.. (1995). Cyclosporin A toxicity: MRI appearance of the brain. Pediatric Radiology. 25(3). 180–183. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact